- Home
- NCTY vs VRCA Comparison
NCTY vs VRCA Comparison
Compare NCTY & VRCA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | NCTY | VRCA |
|---|---|---|
| Founded | 1999 | 2013 |
| Country | China | United States |
| Employees | N/A | N/A |
| Industry | Business Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 97.7M | 87.5M |
| IPO Year | 2004 | 2018 |
Fundamental Metrics
Financial Performance| Metric | NCTY | VRCA |
|---|---|---|
| Price | $5.63 | $5.11 |
| Analyst Decision | | Buy |
| Analyst Count | 0 | 3 |
| Target Price | N/A | ★ $17.00 |
| AVG Volume (30 Days) | 21.1K | ★ 130.4K |
| Earning Date | 01-01-0001 | 01-01-0001 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | $372.93 |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $5.00 | $0.39 |
| 52 Week High | $15.98 | $9.82 |
Technical Indicators
Market Signals| Indicator | NCTY | VRCA |
|---|---|---|
| Relative Strength Index (RSI) | 45.56 | 30.48 |
| Support Level | $5.02 | $3.96 |
| Resistance Level | $7.37 | $5.23 |
| Average True Range (ATR) | 0.42 | 0.42 |
| MACD | 0.06 | -0.03 |
| Stochastic Oscillator | 49.03 | 7.94 |
Price Performance
Historical ComparisonAbout NCTY The9 Limited American Depository Shares
The9 Ltd operates a cryptocurrency mining business. It provides computing power, or hash rate, to a Bitcoin mining pool and is entitled to receive a fractional share of Bitcoin award from the Bitcoin mining pool in return. The company generates its revenues from customers in Greater China, Asia/Eastern Europe, and North America. Its segments are: Crypto mining business, and Other, out of which Crypto mining business derives maximum revenue.
About VRCA Verrica Pharmaceuticals Inc.
Verrica Pharmaceuticals Inc is a dermatology therapeutics company engaged in the development and commercialization of novel treatments that provide a meaningful benefit for people living with skin diseases. Its product candidate, VP-102, is developed for the treatment of molluscum contagiosum, or molluscum, a contagious and pediatric viral skin disease, and common warts.